Increased Expression of Yes-Associated Protein 1 in Hepatocellular Carcinoma with Stemness and Combined Hepatocellular-Cholangiocarcinoma by 源��쁽湲� & 諛뺤쁺�뀈
Increased Expression of Yes-Associated Protein 1 in
Hepatocellular Carcinoma with Stemness and Combined
Hepatocellular-Cholangiocarcinoma
Gi Jeong Kim1, Hyunki Kim1*, Young Nyun Park1,2*
1Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea, 2 Integrated Genomic Research Center for Metabolic Regulation, Yonsei
University College of Medicine, Seoul, Republic of Korea
Abstract
Combined hepatocellular-cholangiocarcinoma (cHC-CC) and some hepatocellular carcinomas (HCCs) express stemness-
related markers, such as epithelial adhesion molecule (EpCAM) and keratin 19 (K19), the expression of which has been
reported to be associated with more aggressive behavior therein than in HCCs without. Yes-associated protein 1 (YAP1), a
potential oncogene, is known to promote stem cell proliferation. In the present study, YAP1 expression and
clinicopathological features were evaluated and compared among three groups comprising 36 HCCs that expressed both
EpCAM and K19, 64 HCCs that did not express EpCAM and K19, and 58 cHC-CCs, which consisted of 38 cases of the classical
type and 20 cases of the intermediate-cell subtype. YAP1 expression was more frequently noted in EpCAM(+)/K19(+) HCCs
(55.6%) and in cHC-CCs (67.2%) than in EpCAM(2)/K19(2) HCCs (17.2%) (P,0.001 for both). In cHC-CCs, YAP1 expression
was observed in 63% of classical type cHC-CCs and in 75% of the intermediate subtype; moreover, such expression was
correlated with poorer histological differentiation (P= 0.017) and was more frequently noted in transition zones than in HCC
areas (P= 0.060). Disease-free and overall survival showed a statistically significant difference among the three groups:
disease-free survival was highest for EpCAM(2)/K19(2) HCCs and lowest for cHC-CCs, with EpCAM(+)/K19(+) HCCs falling in
between (P,0.05). Overall survival rate was lower in HCCs and cHC-CCs with YAP1 expression compared to those without
(P= 0.05), whereas disease-free survival showed no significant difference according to YAP1 expression. Increased YAP1
expression was more frequently found in cHC-CCs and HCCs with stemness than in HCCs without, and a YAP1 pathway is
suggested to be involved in the obtainment stemness characteristics in HCCs and cHC-CCs.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
malignancy worldwide and the third greatest cause of cancer-
related mortality, especially in Asia and Africa.[1] Combined
hepatocellular and cholangiocarcinoma (cHC-CC), an uncommon
subtype that accounts for approximately 1% of all primary liver
tumors, comprises morphologically and phenotypically mixed
elements of HCC and cholangiocarcinoma (CC).[2,3] cHC-CCs
can be categorized as classical type or subtypes with stem cell
features. The latter can further be subcategorized into typical
subtype, intermediate-cell subtype, and cholangiocellular sub-
type.[3]
Recent advances in the study of cancer stem cells have indicated
that cancer stem cells play a critical role in tumor growth and the
progression of HCCs, contributing to their ability to self-renew,
differentiate, and generate metastatic tumors in local or distant
organs.[4–8] HCCs expressing stemness-related markers, includ-
ing epithelial cell adhesion molecule (EpCAM), keratin 19 (K19),
CD90, and CD133, are known to exhibit more aggressive
biological behavior and worse prognosis than HCCs that express
no stemness-related markers.[5,9–11] As well, cHC-CCs, which
also express stemness-related markers, have been reported to show
more aggressive behavior than HCCs.[12,13]
Yes-associated protein 1 (YAP1) is a major downstream target of
the Hippo-signaling pathway, an evolutionarily conserved path-
way from Drosophila to humans that is known to control organ size
during development.[14–16] Regulation of the Hippo-signaling
pathway is known to be mediated by phosphorylation and
subcellular localization of YAP1. Activation of the Hippo-signaling
pathway induces phosphorylation of YAP1, which prevents the
translocation thereof to the nucleus. Instead, phosphorylated
YAP1 remains in the cytoplasm, where it is degraded by
proteasomes. When the Hippo-signaling pathway is inactivated,
dephosphorylated YAP1 is translocated to the nucleus where it
interacts with transcription factors, eventually leading to the
proliferation of cells to various organ systems.[17–20] One
previous study using transgenic mice with liver-specific YAP1
overexpression revealed significant increases in liver size and
number of primary liver tumors morphologically resembling cHC-
CC in humans.[21]
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To our knowledge, the expression of YAP1 has not been
investigated in primary liver cancers with stemness features. In this
study, YAP1 expression patterns and clinicopathological charac-
teristics were compared among HCCs with and without stemness-
related markers and cHC-CCs.
Materials and Methods
Case selection and clinicopathological analysis
A total of 158 cases of primary liver carcinoma showing the
following features were studied: (1) 36 HCCs expressing both
EpCAM and K19 [EpCAM(+)/K19(+)], (2) 64 HCCs without
expression of both EpCAM and K19 [EpCAM(2)/K19(2)], and
(3) 58 cHC-CCs. The cHC-CCs included 38 cases of classical type
cHC-CC and 20 cases of the intermediate-cell subtype.
Tumor specimens were fixed in 10% buffered formalin and
representative sections were submitted for histological examina-
tion. The histopathological variables recorded for each case
included tumor size, multiplicity, differentiation according to a
three-tiered grading system (well, moderately and poorly differen-
tiated), vascular invasion, and intrahepatic metastasis. Clinical
features including age, sex, etiology, and follow-up data were
obtained from hospital charts. There were 55 cases with a history
of preoperative treatment including 44 cases of transcatheter
arterial chemoembolization (TACE), one case of concurrent
chemoradiotherapy (CCRT), five cases of TACE and CCRT,
one case of chemotherapy, and four cases of radiofrequency
ablation. This study was approved by the Institutional Review
Board of Severance Hospital, Yonsei University College of
Medicine (Seoul, Korea). The Institutional Review Board waived
the need for consent in this study (4-2013-0272).
Immunohistochemical staining
The expressions of YAP1, EpCAM, and K19 were evaluated by
immunohistochemical staining in representative sections of
formalin-fixed, paraffin-embedded (FFPE) tissues. Primary anti-
bodies for YAP1 (1:100, Cell Signaling Technology, Danvers, MA,
USA), EpCAM (1:1000, Calbiochem, Merck, Darmstadt, Ger-
many), and K19 (1:100, Dako, Carpinteria, CA, USA) were used.
Briefly, 4-mm-thick sections of FFPE tissues were deparaffinized
and rehydrated. After treatment with a 3% hydrogen peroxide
solution for 20 min to block endogenous peroxidases, the sections
were pretreated in 10 mM citrate buffer (pH 6.0) in a microwave
oven for 20 min for antigen retrieval. After incubation with the
primary antibodies, the sections were then processed using the
EnVisionTM Detection System (Dako) according to the manufac-
turer’s instructions, and 3, 39-diaminobenzidine tetrahydrochlor-
ide was used as a chromogen. All sections were counterstained
with Mayer hematoxylin.
The immunoreactivities of YAP1, EpCAM, and K19 were
evaluated by two independent observers (G. J. Kim and H. Kim).
Conflicting cases were reviewed and discussed until a consensus
was obtained. For the assessment of YAP1 expression, nuclear
YAP1 expression of bile ductular epithelial cells was used as an
internal positive control with moderate intensity. Non-tumor
hepatocytes were used as an internal negative control. YAP1
expression was graded according to nuclear expression intensity:
weak, moderate, or strong expression. Cases showing YAP1
expression in less than 5% of the tumor cells of any intensity grade
or those of weak intensity were regarded as negative (no YAP1
expression), while cases showing moderate to strong intensities in
more than 5% of the tumor cells were regarded as positive for
YAP1 expression.
For expression of EpCAM and K19, membranous or cytoplas-
mic expression in more than 5% of the tumor cells was considered
positive. Bile ductular epithelial cells were used as an internal
positive control for EpCAM and K19. All cHC-CCs were positive
for both EpCAM and K19.
Statistical analyses
Statistical analyses were performed using SPSS software version
19.0 for Windows (SPSS Inc., Chicago, IL, USA). Fisher’s exact
test was used for analysis of categorical variables. Continuous
variables were analyzed using one-way analysis of variance
(ANOVA) or Student’s t-test; these results are expressed as the
mean 6 standard deviation. Histological grades were compared
using the Mann–Whitney U test. On survival analysis, clinico-
pathologic variables were dichotomized and analyzed according to
their effect on prognosis. Disease-free survival and overall survival
analysis was performed using the Kaplan–Meier method, and
differences between the groups were assessed using the log-rank
test. Univariate and multivariate survival analyses were carried out
using Cox proportional hazard regression models. Only variables
significant on the univariate analysis of factors affecting survival
were used in the multivariate analysis. Estimated relative risks of
death were expressed as adjusted hazard ratios (HR) and
corresponding 95% confidence intervals (95% CI). All P-values
less than 0.05 were regarded as statistically significant.
Results
Clinicopathological features of EpCAM(2)/K19(2) HCCs,
EpCAM(+)/K19(+) HCCs, and cHC-CCs
The clinicopathological characteristics of EpCAM(2)/K19(2)
HCCs, EpCAM(+)/K19(+) HCCs, and cHC-CCs are summarized
in Table 1. Both EpCAM(+)/K19(+) HCCs and cHC-CCs
developed in patients of younger age than EpCAM(2)/K19(2)
HCCs (P=0.001 and P=0.005, respectively). Tumor size was
larger in the cHC-CCs than in HCCs (cHC-CCs vs. EpCAM(2)/
K19(2) HCCs, P,0.001; cHC-CCs vs. EpCAM(+)/K19(+)
HCCs, P=0.033). cHC-CCs also more frequently presented as a
single lesion than EpCAM(2)/K19(2) HCCs and EpCAM(+)/
K19(+) HCCs (P=0.032 and P=0.002, respectively). Vascular
invasion was more frequently observed in cHC-CCs than in HCCs
(cHC-CCs vs. EpCAM(2)/K19(2) HCCs, P,0.001; cHC-CCs vs.
EpCAM(+)/K19(+) HCCs, P=0.025). Additionally, EpCAM(+)/
K19(+) HCCs and cHC-CCs exhibited poorer histological
differentiation than EpCAM(2)/K19(2) HCCs (P,0.001 for
both). Among cHC-CCs, the classical type was more frequently
related to human hepatitis B virus or hepatitis C virus infection
than the intermediated-cell subtype (P=0.001). There was no
difference between the two types in terms of sex, age, tumor size,
differentiation, et al. (Table S1).
YAP1 expression in EpCAM(2)/K19(2) HCCs, EpCAM(+)/
K19(+) HCCs, and cHC-CCs
YAP1 expression was found in 11/64 (17.2%) EpCAM(2)/
K19(2) HCCs, 20/36 (55.6%) EpCAM(+)/K19(+) HCCs, and
39/58 (67.2%) cHC-CCs (Table 1) (Figure 1). YAP1 expression
was significantly, more frequently observed in EpCAM(+)/K19(+)
HCCs and cHC-CCs than in EpCAM(2)/K19(2) HCCs
(P,0.001 for both). There was no significant difference in YAP1
expression between EpCAM(+)/K19(+) HCCs and cHC-CCs.
In cHC-CCs, YAP1 expression was present in 24/38 (63.2%)
classical type cHC-CCs and in 15/20 (75.0%) intermediate
subtype cHC-CCs with stem cell features, a difference that was
not statistically significant. YAP1 expression was further analyzed
YAP1 in Liver Cancer with Stemness
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Table 1. Clinicopathological features and YAP1 expression in HCCs and combined hepatocellular-cholangiocarcinomas (cHC-CCs).
Group 1 Group 2 Group3
EpCAM(2)/K19(2)
HCCs (%) (n=64)
EpCAM(+)/K19(+) HCCs
(%) (n=36)
cHC-CCs (%)
(n=58) Group 1 vs. 2 Group 1 vs. 3 Group 2 vs. 3
Sex 0.892 0.810 0.943
Male 54 (84.4) 30 (83.3) 48 (82.8)
Female 10 (15.6) 6 (16.7) 10 (17.2)
Age (years) 59.669.7 52.4611.8 54.4610.5 0.001 0.005 0.378
Etiology 0.239 0.003 0.161
Non-viral 7 (10.9) 7 (19.4) 19 (32.8)
HBV 50 (78.2) 28 (77.8) 35 (60.3)
HCV 7 (10.9) 1 (2.8) 4 (6.9)
Tumor size (mm) 33.4616.5 38.4621.8 50.1630.6 0.204 ,0.001 0.033
Differentiation 0.001 0.001 0.903
Well 27 (42.2) 3 (8.3) 10 (17.2)
Moderate 30 (46.9) 26 (72.2) 33 (56.9)
Poor 7 (10.9) 7 (19.5) 15 (25.9)
Vascular invasion 0.199 ,0.001 0.025
Absence 37 (57.8) 16 (44.4) 13 (22.4)
Presence 27 (42.2) 20 (55.6) 45 (77.6)
Multiplicity 0.251 0.032 0.002
Single 54 (84.4) 27 (75.0) 56 (96.6)
Multiple 10 (15.6) 9 (25.0) 2 (3.4)
Intrahepatic metastasis 0.617 0.003 0.071
Absence 62 (96.9) 34 (94.4) 46 (79.3)
Presence 2 (3.1) 2 (5.6) 12 (20.7)
Preoperative treatment 0.068 0.179 0.532
No 47 (73.4) 20 (55.6) 36 (62.1)
Yes 17 (26.6) 16 (44.4) 22 (37.9)
YAP1 expression* ,0.001 ,0.001 0.255
Negative 53 (82.8) 16 (44.4) 19 (32.8)
Positive 11 (17.2) 20 (55.6) 39 (67.2)
HCC, hepatocellular carcinoma; cHC-CC, combined hepatocellular-cholangiocarcinoma
*Nuclear YAP1 expression with moderate to strong intensities in more than 5% of the tumor cells were regarded as positive.
doi:10.1371/journal.pone.0075449.t001
Figure 1. EpCAM and K19 expression in hepatocellular carcinoma (HCC). (A-D) HCC expressing both EpCAM and K19. The expression of
EpCAM was mainly membranous, and K19 showed cytoplasmic expression in tumor cells. Nuclear expression of YAP1 was noted. (E-H) HCC without
expression of both EpCAM and K19. There was no nuclear expression of YAP1. (Original magnification,6200).
doi:10.1371/journal.pone.0075449.g001
YAP1 in Liver Cancer with Stemness
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in each histological component of classical type cHC-CCs (this
analysis was performed in 29 cases of classical type cHC-CC due
to a shortage of tissues). In doing so, positive expression was found
in 8/29 (27.6%) HCC areas, 12/29 (41.4%) cholangiocarcinoma
(CC) areas, and 15/29 (51.7%) transitional zones (Table 2)
(Figure 2). YAP1 expression was more frequently recoded in
transitional zones than in HCC areas (P=0.060), although this
was not statistically significant. The intermediate-cell subtype of
cHC-CCs with stem cell features predominantly consisted of
tumor cells with intermediate features between hepatocytes and
cholangiocytes, which showed no zonal pattern of YAP1
expression.
The clinicopathological characteristics of HCCs and cHC-CCs
according to YAP1 expression are summarized in Table 3. Among
EpCAM(+)/K19(+) HCCs, cases with YAP1 expression more
frequently manifested as a single lesion than those that did not
express YAP1 (P=0.005). Among cHC-CCs, the expression of
YAP1 was associated with poorer differentiation (P=0.017),
whereas both EpCAM(2)/K19(2) HCCs and EpCAM(+)/
K19(+) HCCs showed no difference in tumor differentiation
according to YAP1 expression. There were no differences in tumor
size and vascular invasion according to YAP1 expression for all
groups.
Survival analysis in EpCAM(2)/K19(2) HCCs, EpCAM(+)/
K19(+) HCCs, and cHC-CCs
Overall survival and disease-free survival were evaluated for 152
patients, including 61 cases of EpCAM(2)/K19(2) HCC, 35 cases
of EpCAM(+)/K19(+) HCC, and 56 cases of cHC-CC. Six
patients who died within one month after an operation were
excluded from the survival analysis to avoid any influence of
perioperative mortality. The median follow-up time after surgical
resection was 32.8 months (4.3–128.7) and 34 patients died of
HCC or cHC-CC during follow-up. Disease-free survival showed
a statistically significant difference among the three groups:
disease-free survival rate was highest for EpCAM(2)/K19(2)
HCCs and lowest for cHC-CCs, with EpCAM(+)/K19(+) HCCs
falling in between (P=0.002) (Fig. 3A). Overall survival also
revealed a statistically significant difference among the three
groups (P,0.001) (Fig. 3B). Among the patients with cHC-CC,
there was no difference between classical type and intermediate-cell
subtype patients in overall survival and disease-free survival rate
(Figure S1).
When primary liver cancers were divided into two groups
according to YAP1 expression, there were 67 cases with YAP1
expression and 85 cases without. Disease-free survival showed no
significant difference between these two groups, whereas overall
survival rate was relatively lower in primary liver cancers with
YAP1 expression compared to those that did not express YAP1
(P=0.050) (Fig. 3C and 3D).
Univariate analysis revealed that larger tumor size ($4 cm)
(P=0.006), history of preoperative treatment (P,0.001), vascular
invasion (P,0.001), intrahepatic metastasis (P,0.001), and the
histologic groups of cHC-CC and EpCAM(+)/K19(+) HCC
(P=0.004) were adverse prognostic factors affecting disease-free
survival after resection. In regards to overall survival, larger tumor
size ($4 cm) (P,0.001), vascular invasion (P,0.001), intrahepatic
metastasis (P,0.001) and the histologic groups of cHC-CC and
Table 2. YAP1 expression in each histologic component of combined hepatocellular-cholangiocarcinomas (classic type).
YAP1 expression* HCC area CC area Transition zone
Transition vs.
HCC area
Transition vs. CC
area HCC vs. CC area
Positive 8 (27.6%) 12 (41.4%) 15 (51.7%) 0.060 0.430 0.269
Negative 21 (72.4%) 17 (58.6%) 14 (48.3%)
HCC, hepatocellular carcinoma; CC, cholangiocarcinoma
*Nuclear YAP1 expression with moderate to strong intensities in more than 5% of the tumor cells were regarded as positive.
doi:10.1371/journal.pone.0075449.t002
Figure 2. YAP1 expression in combined hepatocellular cholangiocarcinoma (cHC-CC). (A-F) Pathological features and YAP1 expression are
shown in each component of classical type combined hepatocellular cholangiocarcinoma, including a hepatocellular carcinoma (HCC) area (A, B), a
cholangiocarcinoma (CC) area (C, D), and a transitional zone (E, F). YAP1 expression is evident in the nuclei of tumor cells in CC areas (D) and
transitional zones (F) in contrast to weak nulcear YAP1 expression in HCC areas (B). (G-H) Intermediate subtype of cHC-CC with stem cell features
showing strong nuclear YAP1 expression. (Original magnification,6200).
doi:10.1371/journal.pone.0075449.g002
YAP1 in Liver Cancer with Stemness
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EpCAM(+)/K19(+) HCC (P=0.002) were revealed as adverse
prognostic factors (Table 4).
Multivariable analysis indicated that history of preoperative
treatment (HR=2.063, P=0.004) and vascular invasion
(HR=2.240, P=0.007) were independent prognostic factors for
disease-free survival after resection. For overall survival, larger
tumor size ($4 cm) (HR=3.448, P=0.008), vascular invasion
(HR=7.135, P=0.009), and the histologic groups of cHC-CC
and EpCAM(+)/K19(+) HCC (P=0.034) were shown to be
independent prognostic factors on multivariable analysis (Table 5).
Discussion
Among morphologically pure HCCs, cases that express
stemness-related markers, such as EpCAM, K19, CD133, etc.,
have been reported to exhibit more aggressive clinicopathological
features, including more frequent vascular invasion, increased
angiogenesis, higher recurrence rate, and worse progno-
sis.[9,10,22,23] In this study, EpCAM(+)/K19(+) HCCs showed
poorer histological differentiation, greater vascular invasion, and
worse prognosis than EpCAM(2)/K19(2) HCCs.
cHC-CCs are rare primary liver tumors, and can be categorized
into classical type cHC-CCs and subtypes with stem cell
features.[3] Classical type cHC-CCs contain HCC areas, CC
areas and transitional zones, which comprise tumor cells with
intermediate morphology resembling stem/progenitor cells. Sub-
types with stem cell features include the typical subtype,
intermediate-cell subtype, and cholangiocellular subtype, and
tumor cells that have phenotypical or immunophenotypical
features of stem/progenitor cells are the main component.[3]
The gene signatures associated with early liver development and
stem cells have been reported to be significantly enriched in cHC-
CC.[24] These features suggest that cHC-CC is closely associated
with stemness. Moreover, cHC-CCs have been reported to exhibit
aggressive characteristics of greater lymph node involvement,
vascular invasion, and worse prognosis than HCC.[13,25–27] The
present study also revealed that cHC-CCs show more aggressive
characteristics of larger tumor size, more frequent vascular
invasion and poorer differentiation than EpCAM(2)/K19(2)
HCCs. Among these characteristics, larger tumor size and more
frequent vascular invasion were also more frequently noted in
cHC-CCs than in EpCAM(+)/K19(+) HCCs. Moreover, disease-
free survival and overall survival showed a statistically significant
Figure 3. Kaplan–Meier’s plot analysis for disease-free survival and overall survival in HCCs and combined hepatocellular-
cholangiocarcinomas (cHC-CCs). Kaplan–Meier’s plot analysis for disease-free survival (A) and overall survival (B) showing a significant difference
among EpCAM(2)/K19(2) HCCs, EpCAM(+)/K19(+) HCCs, and cHC-CCs. Overall survival was relatively worse in HCCs and cHC-CCs with YAP1
expression (D), whereas there was no significant difference in disease-free survival between the two groups.
doi:10.1371/journal.pone.0075449.g003
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difference among cHC-CCs, HCCs with stemness, and HCCs
without stemness: disease-free survival rate was highest in
EpCAM(2)/K19(2) HCCs and lowest in cHC-CCs, with
EpCAM(+)/K19(+) HCCs falling in between.
In a previous study, transgenic mice with liver-specific YAP1
overexpression were reported to develop primary liver tumors,
which morphologically resembled human cHC-CCs.[21] In the
present study, YAP1 expression was found in 67% of cHC-CCs,
56% of EpCAM(+)/K19(+) HCCs, and 17% of EpCAM(2)/
K19(2) HCCs. Such expression was more frequently found in
EpCAM(+)/K19(+) HCCs and cHC-CCs than in EpCAM(2)/
K19(2) HCCs. In cHC-CCs, YAP1 expression was associated
with poorer histological differentiation, and was more frequently
noted in transitional zones with features of stem/progenitor cells,
compared to HCC areas, although this was not statistically
significant.
YAP1 is known to have the ability to induce epithelial
mesenchymal transition (EMT), the differentiation of polarized
epithelial cells to contractile and motile mesenchymal cells.[28]
EMT induction by ectopic expression of either Snail or Twist
transcription factors was also reported to lead to cancer stem-cell
properties in human breast cancer cells.[29] Interestingly, our
previous study revealed that HCCs expressing K19 and/or
EpCAM show upregulation of EMT-associated genes and more
invasive characteristics than those without.[9] In this study,
YAP1 expression was significantly higher in HCCs with
Table 4. Univariate analysis of disease-free and overall survival rate.
Disease-free survival Overall survival
Variable N HR 95% CI P HR 95% CI P
Sex
Female 25 1 1
Male 127 1.021 0.546–1.909 0.946 1.670 0.588–4.745 0.336
Age (years)
,50 43 1 1
$50 109 1.395 0.791–2.461 0.249 1.344 0.604–2.992 0.469
Etiology
Viral (HBV, HCV) 121 1 1
Non-viral 31 1.371 0.790–2.381 0.261 1.307 0.611–2.798 0.490
Tumor size
,4 cm 83 1 1
$4 cm 69 1.974 1.213–3.211 0.006 6.925 2.859–16.769 ,0.001
Multiplicity
Single 134 1.000 1
Multiple 18 1.437 0.731–2.824 0.292 1.251 0.381–4.101 0.712
Differentiation
Well/moderate 124 1 1
Poor 28 1.554 0.885–2.726 0.124 1.836 0.867–3.887 0.112
Preoperative treatment
No 101 1 1
Yes 51 2.307 1.422–3.744 ,0.001 0.978 0.476–2.009 0.951
Vascular invasion
Absence 63 1 1
Presence 89 2.841 1.636–4.935 ,0.001 14.769 3.534–61.715 ,0.001
Intrahepatic metastasis
Absence 136 1 1
Presence 16 3.298 1.712–6.350 ,0.001 4.563 2.035–10.232 ,0.001
Histologic group
EpCAM(2)/K19(2) HCCs 61 1 0.004 1 0.002
EpCAM(+)/K19(+) HCCs 35 2.148 1.092–4.226 0.026 16.533 2.091–130.707 0.008
cHC-CCs 56 2.812 1.530–5.167 0.001 29.442 3.953–219.286 0.001
YAP1 expression*
Negative 85 1 1
Positive 67 1.261 0.777–2.046 0.346 1.990 0.988–4.008 0.050
*Nuclear YAP1 expression with moderate to strong intensities in more than 5% of the tumor cells were regarded as positive.
doi:10.1371/journal.pone.0075449.t004
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stemness than in those without. Taken together, our results
suggest that the Hippo-YAP1 pathway might be involved in the
pathogenesis of liver cancers with stemness, such as EpCAM(+)/
K19(+) HCCs and cHC-CCs, which exhibit aggressive biolog-
ical behavior. Additionally, YAP1 expression has been reported
to be related to poor prognosis in several malignancies,
including HCC, non-small cell lung cancer, gastric cancer and
colorectal cancer.[30–33] In this study, overall survival rate was
relatively lower in HCCs and cHC-CCs that expressed YAP1
compared to those that did not, whereas disease free survival
showed no difference according to YAP1 expression. Also,
YAP1 expression was revealed as a significant prognostic factor
affecting overall survival on univariate analysis, but not on
multivariate analysis.
In conclusion, this is the first study to provide clinicopatholog-
ical evidence that YAP1 is more frequently expressed in HCCs
expressing stemness-related markers (EpCAM and K19) and in
cHC-CCs, compared to HCCs lacking such expression. Our
findings suggest that YAP1 expression may contribute to the gain
of stemness in HCCs and cHC-CCs, and could be a potential
therapeutic target for treatment of these tumors.
Supporting Information
Figure S1 Kaplan–Meier’s plot analysis for disease-free
survival and overall survival in combined hepatocellu-
lar-cholangiocarcinomas (cHC-CCs). There was no differ-
ence between classical type and intermediate-cell subtype patients
in disease-free survival (A) and overall survival rate (B).
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